Mumbai: Piramal Pharma Limited (PPL) (NSE: PPLPHARMA, BSE: 543635) has published its FY2025 Sustainability Report under the theme “Innovating Responsibly. Growing Sustainably.”
The report demonstrates measurable progress across its four strategic pillars: Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity.
Piramal Pharma’s Sustainability Progress in FY2025
The FY2025 Sustainability Report showcases how Piramal Pharma continues to integrate responsible practices across its operations worldwide. The company has strengthened governance frameworks, accelerated decarbonization, advanced diversity and inclusion, and enhanced community impact through its CSR programs. The report has been externally assured by DNV, reinforcing its credibility and transparency.
Also Read: Akums Partners with Government of Zambia to Establish Pharmaceutical Manufacturing Facility
Business Resilience and Governance
- 50% independent directors on the Board; 30% women representation, above statutory norms.
- Zero data breaches and 100% completion of Code of Conduct training.
- 26.5% of critical suppliers assessed on sustainability, with a target to build capacity for 30% by FY2026.
Quality & Excellence
- 36 regulatory inspections successfully completed, including two by the USFDA.
- 165 customer audits conducted globally.
- Digital transformation driven by Catalyst NxGen (S/4HANA) with 17 governance dashboards.
- Customer satisfaction scores: 85% (CDMO/PPS) and 87% (Critical Care/PCC).
Responsible Operations and Climate Action
- 6% reduction in Scope 1 & 2 emissions (YoY).
- 7.8% increase in renewable energy adoption; 20.2% of total energy from bioenergy.
- Zero hazardous waste to landfill and 90% recycling target for non-hazardous waste.
- 2.10 lakh kilolitres of freshwater conserved through water stewardship initiatives.
- 2,000+ saplings planted; 30% green cover maintained across Indian sites.
- Biomass briquettes project at the Digwal facility, replacing coal-fired boilers.
Stakeholder Centricity and DE&I Initiatives
- 30% women representation on the Board.
- Women comprise 20% of the global workforce; 2.7% YoY increase.
- 63.3% of campus hires are women.
- 100% of employees covered by ESG training.
- Lost Time Injury Rate (LTIR) improved by 45%, reducing LTIR to 0.05.
CSR and Community Impact
In FY2025, Piramal Pharma, in collaboration with Piramal Foundation, expanded its CSR outreach to 112 aspirational districts, focusing on education, healthcare, women’s empowerment, and safe water practices.
Also Read: AI in Biopharma: ThinkBio Ai and UST Launch Strategic Alliance
The company invested ₹5.34 crore in initiatives such as school infrastructure upgrades, teacher training, and public health campaigns. Employee volunteering supported plantation drives, health awareness sessions, and community projects.
Additionally, PPL launched a women-led skill development program near its Digwal facility in partnership with the Life Sciences Sector Skill Development Council. The company also supported the Aspirational Bharat Collaborative (ABC), aiming to uplift 100 million citizens in underserved regions by 2047.
Nandini Piramal, Chairperson of Piramal Pharma Limited, said: “At Piramal Pharma, sustainability is not just a responsibility – it is a deliberate choice. This year, we advanced our decarbonization journey, expanded renewable energy use, and intensified water stewardship and circularity efforts. Our focus on diversity, equity, and inclusion has created a more inclusive workplace, while our CSR initiatives have brought meaningful change to over 200 million people. We remain committed to innovating responsibly and growing sustainably for our patients, communities, and the planet.”
Piramal Pharma’s Commitment to Sustainable Growth
Aligned with GRI standards, SASB, and UNGC frameworks, the FY2025 Sustainability Report demonstrates Piramal Pharma’s commitment to responsible capital allocation, sustainable operations, and impactful stakeholder engagement.
The complete report is available at: Piramal Pharma FY2025 Sustainability Report
.
